title: Luteal-long GnRH agonist versus flexible-multidose GnRH antagonist protocols for overweight and obese patients who underwent ICSI.
abstract: A total of 413 consecutive infertile patients (572 cycles) with a body mass index (BMI) of ≥ 25 kg/m(2) were enrolled into the study. The luteal-long GnRH agonist group (Group I) constituted 211 patients (300 cycles) and the flexible-multidose GnRH antagonist group (Group II) constituted 202 patients (272 cycles). The duration of stimulation (d) (10.1 ± 2.5 vs. 9.2 ± 2.0; p < 0.01); the total dose of gonadotrophin used (IU) (3,099.4 ± 2,885.0 vs. 2,684.0 ± 1,046.4; p < 0.05) and the E2 level on the day of hCG (pg/ml) (2,375.8 ± 1,554.6 vs. 1,905.6 ± 1,598.8; p < 0.01) were significantly lower in Group II when compared with Group I. However, the ongoing pregnancy per embryo transfer (37.0% vs. 25.7%; p < 0.05) and the implantation rate (25.7% vs. 15.6%; p < 0.01) were significantly lower in Group II when compared with Group I. In conclusion, we noted that the luteal-long GnRH agonist protocol produced higher implantation rates and higher clinical-ongoing pregnancy rates in overweight and obese patients when compared with the flexible-multidose GnRH antagonist protocol.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Hacettepe University.
authors.forename: I
authors.initials: I
authors.lastname: Esinler
authors.forename: G
authors.initials: G
authors.lastname: Bozdag
authors.forename: D
authors.initials: D
authors.lastname: Esinler
authors.forename: K S
authors.initials: KS
authors.lastname: Lale
authors.forename: H
authors.initials: H
authors.lastname: Yarali
mesh_terms: D000328:Adult; D002985:Clinical Protocols; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000819:agonists / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D006062:Gonadotropins / Q000008:administration & dosage; D006801:Humans; D007246:Infertility / Q000628:therapy; D016729:Leuprolide / Q000008:administration & dosage*; D008183:Luteal Phase; D009765:Obesity / Q000150:complications*; D050177:Overweight / Q000150:complications; D011247:Pregnancy; D018873:Pregnancy Rate; D027724:Reproductive Techniques, Assisted; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D003278:Contraceptives, Oral, Hormonal; D005300:Fertility Agents, Female; D006062:Gonadotropins; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide; C062876:cetrorelix
keywords: COH; GnRH agonist; GnRH antagonist; ICSI; IVF; OHSS; pregnancy rates